Loncar Cancer Immunotherapy ETF (CNCR) 是一家上市公司 属于 金融服务 板块，经营于 资产管理 行业.
CNCR 拥有 IPO日期为 2015-10-14, 在 NASDAQ Global Market, 市值为 $7.04M.
The index is composed of the common stock of approximately 30 pharmaceutical or biotechnology companies identified by the fund's index provider, as having a high strategic focus on the development of drugs that harness the body's own immune system to fight cancer. The adviser attempts to invest all, or substantially all, of its assets in the component securities and ADRs that make up the index. At least 80% of its total assets will be invested in the component securities of the index. The fund is non-diversified.
